Report error Found 37 Enz. Inhib. hit(s) with all data for entry = 50045051
TargetSerine/threonine-protein kinase Chk1(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataEC50: 3.30E+3nMAssay Description:Inhibition of full-length Chk1 in HeLa S3 cells assessed as phosphorylation at Ser345 after 4 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataEC50: 570nMAssay Description:Inhibition of full-length Chk1 in HeLa S3 cells assessed as phosphorylation at Ser345 after 4 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 39nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 80nMAssay Description:Inhibition of full-length Chk1 in HeLa S3 cells assessed as phosphorylation at Ser345 after 4 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 84nMAssay Description:Inhibition of full-length Chk1 in HeLa S3 cells assessed as phosphorylation at Ser345 after 4 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 95nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase Chk1(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 96nMAssay Description:Inhibition of full-length Chk1 in HeLa S3 cells assessed as phosphorylation at Ser345 after 4 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 96nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase ATR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 190nMAssay Description:Inhibition of human ATR using ATP substrate measured after 3 hrsMore data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase mTOR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 4.60E+3nMAssay Description:Inhibition of mTOR (unknown origin)More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase mTOR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 7.50E+3nMAssay Description:Inhibition of mTOR (unknown origin)More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PI3Kalpha (unknown origin)More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PI3Kalpha (unknown origin)More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PI3Kalpha (unknown origin)More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of PI3Kalpha (unknown origin)More data for this Ligand-Target Pair
TargetSerine/threonine-protein kinase mTOR(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 1.30E+4nMAssay Description:Inhibition of mTOR (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1.50E+4nMAssay Description:Inhibition of ATM (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 2.40E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
TargetDNA-dependent protein kinase catalytic subunit(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 2.50E+4nMAssay Description:Inhibition of DNAPK (unknown origin)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human ERG channel by dofetilide binding assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Novartis Institutes For Biomedical Research
Curated by ChEMBL
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of human ERG channel by dofetilide binding assayMore data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 4.00E+4nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair












